Children's National Medical Center -D.C. Center for Cancer and Blood Disorders

Washington D.C., District of Columbia 20010

0 studies enrolling now · 2 studies all time

What they study most

Ependymoma, Recurrent or Refractory Pediatric Ependymoma

Studies at this site

• Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma — Stopped early
• Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 — Stopped early